OAβ Test, the screening blood test for Alzheimer’s disease
PeopleBio announced on November 9th that it has signed a contract with Singapore's All Eights to supply a total of $1.7 million worth of Alzheimer's screening kits for three years.
This contract starts from the day the product is registered at the Singapore Health Science Authority, which usually takes about 3 to 6 months. It is a pure administrative procedure that does not require additional clinical trials.
All Eights provides a platform for international diagnostic companies to promote their products in Singapore and Malaysia, providing total services such as licensing, sales marketing, logistics, and technical support.
Sungmin Kang, CEO of PeopleBio, said "I think that supplying an early screening kit to Singapore is the outcome of PeopleBio’s technology and the reflection of need for our products.” “We will also be providing the screening service in connection with hospitals affiliated with the National Neuroscience Institute (NNI), the largest national education center in Singapore for the health of brain, spine, nerves, and muscles.” he added.
He explained the meaning of the contract, saying "This contract will be a stepping stone for entering other countries such as those in Europe, where the population is aging like Singapore and the demand for early diagnosis kits for Alzheimer's disease is high."
Starting with Europe next year, PeopleBio plans to target other overseas countries where are in demand for early screening of Alzheimer's disease.
Headquartered in Seongnam, South Korea, PeopleBio developed its proprietary screening blood test for Alzheimer’s disease, named the ‘OAβ Test’ using the Multimer Detection System (MDS) technology, which can measure the oligomerization levels of beta-amyloid prior to the onset of symptoms.
